Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 9Lymphoma, Non-Hodgkin 9Lymphoma, B-Cell 5Arthritis, Rheumatoid 5Solid Tumors 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Colorectal Neoplasms 3Ovarian Neoplasms 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Spondylitis, Ankylosing 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Esophageal Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × tocilizumab × Clear all
NCT05533775 2026-06-03

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting
65 enrolled

Recurrence

NCT05927571 2026-06-03

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Genentech, Inc.

Phase 1 Recruiting
120 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06372574 2024-09-03

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Genentech, Inc.

Phase 1 Withdrawn

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡